Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lancet
Insulin Resistance & Diabetes

Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice

Grannell A, Al-Najim W, le Roux C. Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice Clin Obes
Body composition

GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice

Sridhar A, Khan D, Flatt PR, Moffett CR, Irwin N. GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice Peptides

Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial

Coelho C, Dobbie LJ, Crane J, Douiri A, Learoyd AE, Okolo O, Panagiotopoulos S, Pournaras DJ, Ramar S, Rubino F, Singhal R, le Roux CW, Taheri S, McGowan B. Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial Int J Obes (Lond)
Insulin Resistance & Diabetes

Pharmacotherapy before and after bariatric surgery

Alabduljabbar K, le Roux CW. Pharmacotherapy before and after bariatric surgery Metabolism

Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting

Alabduljabbar K, Alsaqaaby M, Neff KJ, Crotty M, le Roux CW. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting Endocrine

Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function

De Barra C, Khalil M, Mat A, O'Donnell C, Shaamile F, Brennan K, O'Shea D, Hogan AE. Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function Obesity (Silver Spring)

The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges

Haymond MW, Araújo-Vilar D, Balser J, Lewis JH, Louzado R, Musso C, von Schnurbein J, Wabitsch M; MEASuRE group. The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges Orphanet J Rare Dis

Pharmacotherapy for chronic obesity management: a look into the future

Abdel-Malek M, Yang L, Miras AD. Pharmacotherapy for chronic obesity management: a look into the future Intern Emerg Med

Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function

De Barra C, Khalil M, Mat A, O'Donnell C, Shaamile F, Brennan K, O'Shea D, Hogan AE. Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function Obesity (Silver Spring)

Older posts

Page1 Page2 … Page15 Next →

Search for:

Recent Posts

ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update
ECO2023 Teaching Workshops – Registration Open!
“Addressing Obesity Together” – Press Release

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2023 ASOI